← FDA DRUG APPROVALS
FDA ANDA · ANDA090528
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
Sponsor: TORRENT PHARMS
APPLICATION
ANDA090528
TYPE
ANDA
ORIGINAL APPROVAL
2010-04-06
LATEST ACTION
2023-07-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LOSARTAN POTASSIUM 50MG · TABLET · ORAL
Approval history
2023-07-28Labeling · Supplement 27 · standardAP
2023-07-28Labeling · Supplement 33 · standardAP
2023-07-28Labeling · Supplement 31 · standardAP
2019-09-03Labeling · Supplement 19 · standardAP
2017-02-21Labeling · Supplement 15 · standardAP
2015-08-21Labeling · Supplement 12 · standardAP
2015-08-21Labeling · Supplement 10 · standardAP
2015-08-21Labeling · Supplement 13 · standardAP
2013-03-19Labeling · Supplement 9 · standardAP
2013-03-19Labeling · Supplement 6AP
2013-03-19Labeling · Supplement 2AP
2010-10-06UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.